Dr. Siefker-Radtke on Bempegaldesleukin Plus Nivolumab in Urothelial Carcinoma
February 17th 2019Arlene O. Siefker-Radtke, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the promise of bempegaldesleukin plus nivolumab in the treatment of patients with metastatic urothelial carcinoma.
Read More
Dr. Siefker-Radtke on Next Steps With Erdafitinib in Bladder Cancer
August 31st 2018Arlene O. Siefker-Radtke, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses next steps with erdafitinib in patients with bladder cancer.
Read More
Dr. Siefker-Radtke on the Treatment of FGFR-Altered Bladder Cancer
August 3rd 2018Arlene O. Siefker-Radtke, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with bladder cancer who have fibroblast growth factor receptor (FGFR)-altered tumors.
Read More
Dr. Siefker-Radtke on the Phase II Study of Erdafitinib in Patients With Urothelial Carcinoma
June 29th 2018Arlene O. Siefker-Radtke, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the phase II study of erdafitinib in patients with metastatic or unresectable urothelial carcinoma who have FGFR alterations.
Read More
Dr. Siefker-Radtke on FDA Approval of Avelumab in Bladder Cancer
May 10th 2017Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses the FDA approval of avelumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed after platinum-based therapy.
Read More
Dr. Siefker-Radtke on FDA Approval of Durvalumab in Bladder Cancer
May 2nd 2017Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses the FDA approval of the PD-L1 inhibitor durvalumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed on standard platinum‑based chemotherapy.
Read More
Dr. Siefker-Radtke on FDA Approval of Frontline Atezolizumab in Bladder Cancer
April 18th 2017Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses the FDA approval of the PD-L1 inhibitor atezolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma as a frontline therapy or following progression occurring ≥12 months after neoadjuvant or adjuvant chemotherapy.
Read More
Dr. Siefker-Radtke on PD-L1 as a Biomarker in Bladder Cancer
March 10th 2017Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses why researchers and physicians should reconsider the utility of PD-L1 as a biomarker for patients with bladder cancer.
Read More
Dr. Siefker-Radtke on Advancements in Small Cell Urothelial Cancer
January 8th 2016Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses treatment advancements in small cell urothelial cancer.
Read More